Stock Financial Ratios, Dividends, Split History

B / Barnes Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price57.76
Volume363,800.00
Market Cap ($M)3,270.31
Enterprise Value ($M)3,126.35
Book Value ($M)1,295.59
Book Value / Share24.63
Price / Book2.59
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 54,073,407
Weighted Average Number Of Diluted Shares Outstanding 54,605,298
Common Shares Outstanding 53,234,401
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.03
Return on Equity (ROE)0.05
Balance Sheet (mrq) ($M)
Assets2,416.20
Liabilities1,120.61
Quick Ratio1.56
Current Ratio2.27
Income Statement (mra) ($M)
Sales Revenue Net1,436,499,000.00
Operating Income210.28
Net Income59.41
Earnings Per Share Basic1.10
Earnings Per Share Diluted1.09
Cash Flow Statement (mra) ($M)
Cash From Operations203.92
Cash from Investing-68.04
Cash from Financing-68.04
Identifiers and Descriptors
CUSIP067806109
Central Index Key (CIK)9984
Related CUSIPS
067806909 067861096 067806959

Split History

Stock splits are used by Barnes Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

BRIEF-Barnes Group Inc Declares Quarterly Dividend

2018-05-04 reuters
* BARNES GROUP INC - INCREASED COMPANY’S QUARTERLY CASH DIVIDEND FOURTEEN PERCENT TO $0.16 PER SHARE OF COMMON STOCK Source text for Eikon: Further company coverage: (17-0)

Why Investment Wealth-Builders Seek Leveraged ETFs

2018-04-29 seekingalpha
This article is a deep-dive learning lesson for those new to or confused by our behavioral analysis of Market-Maker price-range forecasts. (80-0)

Barnes' (B) CEO Patrick Dempsey on Q2 2016 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Good morning. My name is Kelly, and I will be your operator today. At this time, I would like to welcome everyone to the Barnes Group Inc. First Quarter 2018 Earnings Conference Call. [Operator Instructions] Thank you. (17-0)

Barnes Group Inc 2018 Q1 - Results - Earnings Call Slides

2018-04-27 seekingalpha
The following slide deck was published by Barnes Group Inc in conjunction with their 2018 Q1 earnings call. (17-0)

Is the Options Market Predicting a Spike in W&T Offshore (WTI) Stock?

2018-04-27 zacks
Investors in W&T Offshore, Inc. (WTI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 18th 2018 $2.00 Put had some of the highest implied volatility of all equity options today. (17-0)

CUSIP: 067806109